Research progress update
Two drugs, one goal
Researchers at MD Anderson launched a first-of-its-kind clinical trial for a particular type of treatment-resistant prostate cancer. They’re combining two drugs — abiraterone and enzalutamide — to block the resistance pathways that arise in each drug alone. The goal of this ongoing study is to decrease the levels of testosterone that drive the cancer.